The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -9,519 |
| Share-based compensation | 14,824 |
| Amortization of intangible assets | 16,988 |
| Depreciation of property and equipment | 3,848 |
| Amortization of other assets | 4,513 |
| Amortization of debt issuance costs | 3,636 |
| Inventory write-down | 7,219 |
| Syndeo inventory write-down | 0 |
| Provision for estimated credit losses | 2,067 |
| Change in fair value of warrant liabilities | -487 |
| Gain on exchange and repurchases of convertible senior notes, net | 18,089 |
| Deferred income taxes | 2,219 |
| Other Operating Activities Cash Flow Statement | -107 |
| Accounts receivable | -5,162 |
| Inventories | -15,792 |
| Prepaid expenses, other current assets, and income tax receivable | -3,423 |
| Accounts payable, accrued expenses, and income tax payable | -7,179 |
| Increase Decrease In Other Operating Capital Net | 6,825 |
| Net cash provided by operating activities | 37,485 |
| Cash paid for intangible assets | 4,860 |
| Cash paid for property and equipment | 303 |
| Cash paid for asset acquisitions | 0 |
| Net cash used for investing activities | -5,163 |
| Repurchase of 2026 notes in connection with exchange | 392,583 |
| Issuance of 2028 notes in connection with exchange, net | 237,601 |
| Repurchase of 2026 notes | 18,372 |
| Payment of tax withholdings on vested stock awards | 1,572 |
| Repurchase of common stock | 0 |
| Payment of accelerated share repurchases | 0 |
| Payment of contingent considerations related to acquisitions | 0 |
| Other, net | 0 |
| Net cash used for financing activities | -174,926 |
| Net change in cash, cash equivalents, and restricted cash | -142,604 |
| Effect of foreign currency translation on cash | 5,214 |
| Cash, cash equivalents, and restricted cash beginning of period | 370,063 |
| Cash, cash equivalents, and restricted cash end of period | 232,673 |
Beauty Health Co (SKIN)
Beauty Health Co (SKIN)